How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Kaleb H Wolfe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Microbial Sensitivity Tests. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Antimicrobial resistance (AMR) affects 2.8 million Americans annually. AMR is identified through antimicrobial susceptibility testing (AST), but current and proposed regulatory policies from the United States Food and Drug Administration (FDA) jeopardize the future availability of AST for many microorganisms. Devices that perform AST must be cleared by the FDA using their susceptibility test interpretive criteria, also known as breakpoints. The FDA list of breakpoints is relatively short. Today, laboratories supplement FDA breakpoints using breakpoints published by the Clinical and Laboratory Standards Institute, using legacy devices and laboratory-developed tests (LDTs). FDA proposes to regulate LDTs, and with no FDA breakpoints for many drug–bug combinations, the risk is loss of AST for key clinical indications and stifling innovation in technology development. Effective solutions require collaboration between manufacturers, infectious diseases clinicians, pharmacists, laboratories, and the FDA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee.
- Department of Pathology, University of Michigan Medical School, Ann Arbor.
- Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
ORCID-Profile: Romney M Humphries
Zitieren
APA
Wolfe, K. H., Pierce, V. M., & Humphries, R. M. (2024). How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae075
Vancouver
Wolfe KH, Pierce VM, Humphries RM. How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae075
BibTeX
@article{Wolfe2024,
author = {Wolfe, Kaleb H and Pierce, Virginia M and Humphries, Romney M},
title = {How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae075}
}
EUVIMED